Divi's Laboratories — Q3 FY26
Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
FY26 CapEx to exceed INR 2,000 crore
Management confirmed that FY26 CapEx will be higher than the earlier guidance of INR 2,000 crore, driven by three new projects with long-term supply commitments.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Constant currency revenue growth ~10.8% for H2
Management expects constant currency revenue growth for the second half to be similar to H1's 10.79%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1